Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $24.50 Consensus Target Price from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned an average rating of “Hold” from the eleven brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $24.50.

A number of analysts have recently issued reports on the company. Lifesci Capital cut Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Wedbush set a $13.00 price objective on shares of Astria Therapeutics and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Oppenheimer downgraded shares of Astria Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. JMP Securities restated a “market perform” rating on shares of Astria Therapeutics in a report on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Astria Therapeutics in a report on Wednesday, January 21st.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds have recently modified their holdings of the stock. Jane Street Group LLC boosted its holdings in Astria Therapeutics by 317.3% in the 1st quarter. Jane Street Group LLC now owns 108,898 shares of the biotechnology company’s stock worth $582,000 after acquiring an additional 82,805 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Astria Therapeutics by 185.8% during the second quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,557 shares in the last quarter. Bailard Inc. purchased a new position in shares of Astria Therapeutics in the second quarter valued at $142,000. JPMorgan Chase & Co. boosted its stake in shares of Astria Therapeutics by 4,607.1% in the second quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company’s stock valued at $9,091,000 after purchasing an additional 1,660,039 shares during the period. Finally, Rhumbline Advisers grew its holdings in Astria Therapeutics by 18.2% during the 2nd quarter. Rhumbline Advisers now owns 75,674 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 11,663 shares in the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Trading Up 0.6%

Shares of ATXS opened at $12.58 on Friday. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $13.29. The firm has a market capitalization of $718.13 million, a P/E ratio of -5.88 and a beta of 0.01. The stock’s fifty day simple moving average is $12.77 and its 200 day simple moving average is $10.05.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The business had revenue of $0.71 million during the quarter, compared to analysts’ expectations of $10.67 million. Sell-side analysts predict that Astria Therapeutics will post -1.65 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.